{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/06/29/3318861/28908/en/Tonix-Pharmaceuticals-Announces-First-Patient-Enrolled-in-Phase-2-HORIZON-Study-of-TNX-102-SL-for-the-Treatment-of-Major-Depressive-Disorder-MDD.html", "message": "News view counter 820271 successfully enlarged"}